No­vo Nordisk joins No­var­tis, Roche in NL­RP3 are­na, bet­ting $70M cash on NASH, car­diometa­bol­ic us­es

As a drug tar­get, the NL­RP3 in­flam­ma­some has drawn se­ri­ous in­ter­est from Big Phar­ma, in­spir­ing a se­ries of M&A deals from No­var­tis and Roche on top of ven­ture in­vest­ments by oth­ers. Now No­vo Nordisk is jump­ing on the band­wag­on — and the Dan­ish phar­ma gi­ant is tak­ing the tar­get where it knows best.

No­vo Nordisk is get­ting its NL­RP3 in­hibitors from Ven­tus Ther­a­peu­tics, a Ver­sant-backed start­up that set out to make some of the best NL­RP3 drugs out there by in­cor­po­rat­ing new in­sights in­to the struc­ture of the tar­get com­plex.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN